Blood sugar and stem cell transplant study
Part of Hormones & metabolism clinical trials.
This study looks at blood sugar problems in people who have had a stem cell transplant from a donor. It may help doctors learn how to better manage or prevent diabetes after a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant from a donor between March 2019 and March 2024.
- Your donor had a blood sugar test before donation.
- You are physically able to do daily activities (WHO score 0-2).
- You have survived at least 12 weeks after the transplant.
- Your liver, kidney, and blood clotting tests are within normal limits.
- You do not have active autoimmune diseases, uncontrolled heart disease, HIV, or hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at heart problems that can happen after a stem cell transplant from a donor (allogeneic). It aims to understand these risks better so doctors can help patients stay healthier after transplant.
This study tracks patients who have had or are planning to have a stem cell transplant. It helps doctors learn more about long-term outcomes and improve care for future patients.
This trial tests if umbilical cord stem cells can improve the success of islet cell transplants for people with diabetes whose own pancreas no longer makes enough insulin. It aims to help patients achieve better blood sugar control and reduce dangerous low blood sugar episodes.
This study looks at how your body processes medications after a stem cell transplant from a donor. It aims to find the best way to test your genes to improve future treatments.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial looks at whether adding gastrin can improve outcomes after an islet cell transplant for people with type 1 diabetes. It may help some participants achieve better blood sugar control, but it also requires close follow-up and immune-suppressing medications to protect the new cells.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.